Table 5.
Relative risk of FP-related toxicity in the intervention group compared to control group
| All patients | DPYD variant carriers | Wild type | |
|---|---|---|---|
| Overall grade ≥3 toxicity | 1.20 (0.92-1.57) | 0.80 (0.32-1.97) | 1.25 (0.95-1.66) |
| FP-related hospitalization | 1.23 (0.75-2.00) | 0.11 (0.01-1.82) | 1.56 (0.93-2.59) |
| Grade 5 toxicity (death) | 0.36 (0.04-2.94) | 0.37 (0.02-7.46) | 0.54 (0.06-4.81) |
All data reported with 95% confidence intervals.
FP, (5-fluorouracil, capecitabine, tegafur(S-1))
Heterozygous, compound heterozygous, and homozygous are pooled together.